MasterCard Partners With PGA and 4 Stocks Riding 52-Week Highs

General Moly (AMEX:GMO) said through its 80 percent-owned Mt. Hope subsidiary, Eureka Moly, that the Bureau of Land Management accepts its reclamation bonding for the Mt. Hope Project and has thus awarded authorization to proceed with surface disturbing activities. The surety program was funded with an initial cash payment of $5.6 million and requires additional cash funding of $11.6 million through the construction process, for an aggregate amount of $17.2 million, which is in alignment with the net cash bonding cost included in the August 2012 capital estimate. This amount covers the first three years of estimated surface disturbance at Mt. Hope, and is subject to ongoing evaluation afterwards. With the surety program in place and the initial contribution funded, the BLM has indicated that the surface disturbance in conformity with the Record of Decision may proceed. Shares closed down 0.48 percent on the day at $4.12, and have been traded in a 52-week range of $2.41 to $4.14.

Icon (NASDAQ:ICLR) reported that all resolutions recommended by the board at the Extraordinary General Meeting of the firm were duly passed by shareholders. These resolutions, which are relating to the proposed conversion to a direct Nasdaq listing for Icon Shares, were set out in the Notice of the EGM sent to shareholders on November 16th and are available on the Icon website. Shares closed up 0.81 percent on the day at $28.54, having been traded in a 52-week range of $16.32 to $28.54.

Catalysts are critical to discovering winning stocks. Check out our newest CHEAT SHEET stock picks now.

Mastercard (NYSE:MA) and the PGA TOUR have extended their marketing relationship through 2016, which will concentrate on further providing MasterCard cardholders golf experiences, access to top PGA TOUR tournaments and properties, along with golf-related savings and offers. Shares closed up 0.73 percent on the day at $492.88, and have been traded in a 52-week range of $336.26 to $494.51.

Moody’s Analytics (NYSE:MCO) announced Tuesday that the Norwegian insurance firm Gjensidige has selected its Solvency II software, RiskIntegrity, to improve its risk management architecture and also help it comply with Solvency II. RiskIntegrity consists of an integrated solution that offers data management and Solvency Capital Requirement calculation and regulatory reporting capabilities. Gjensidige selected Moody’s Analytics Solvency II solution for its out-of-the box regulatory capabilities and user-friendliness, along with Moody’s Analytics expertise in implementing software solutions for large, international organizations. Shares closed up 2.25 percent on the day at $50.79, having been traded in a 52-week range of $32.79 to $49.95.

Mylan (NASDAQ:MYL) has won final FDA approval for its Abbreviated New Drug Application for Quinine Sulfate Capsules, which represent the generic version of Mutual Pharmaceutical’s Qualaquin Capsules, and is an antimalarial drug indicated only for treatment of uncomplicated Plasmodium falciparum malaria. Shares closed up 0.39 percent on the day at $28.30, and have been traded in a 52-week range of $20.21 to $28.22.

Investing Insights: Is This Healthcare Company an Outperform?